Investors Are Craving More from Aptose Biosciences Inc. [APTO] Stocks: Here is Why

Aptose Biosciences Inc. [APTO] stock is down -0.79 while the S&P 500 has risen 0.66% on Thursday, 12/03/20. While at the time of this article, APTO ATR is sitting at 0.40, with the beta value at 1.64. This stock’s volatility for the past week remained at 7.05%, while it was 7.13% for the past 30-day period. APTO has fallen -$0.05 from the previous closing price of $6.31 on volume of 1.02 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 1, December 2020, Aptose to Hold Corporate Update Sunday, December 6th. According to news published on Yahoo Finance, Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers.

Analyst Birdseye View:

The most recent analyst activity for Aptose Biosciences Inc. [NASDAQ:APTO] stock was on September 22, 2020, when it was Initiated with a Buy rating from Alliance Global Partners, which also raised its 12-month price target on the stock to $12. Before that, on October 19, 2020, Cantor Fitzgerald Recapitulated an Overweight rating and elevated its amount target to $10. On February 20, 2020, Maxim Group Initiated a Buy rating and boosted its price target on this stock to $16. On February 06, 2020, H.C. Wainwright Reiterated a Buy rating and increased its price target from $6 to $9. On January 09, 2020, Piper Sandler Initiated an Overweight rating and increased its price target to $10. On March 01, 2019, RBC Capital Mkts Initiated an Outperform rating and boosted its amount on this stock to $6. On November 16, 2018, B. Riley FBR Initiated a Buy rating and boosted its target amount on this stock to $5.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.47 and a peak of $9.25. Right now, according to Wall Street analyst the average 12-month amount target is $10.50. At the most recent market close, shares of Aptose Biosciences Inc. [NASDAQ:APTO] were valued at $6.26. According to the average price forecast, investors can expect a potential return of 52.8%.


If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 1.60 and the whole liability to whole assets at 1.52. It shows enduring liability to the whole principal at 1.06 and enduring liability to assets at 0.01 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 6.08 points at 1st support level, the second support level is making up to 5.86. But as of 1st resistance point, this stock is sitting at 6.71 and at 7.12 for 2nd resistance point.

Aptose Biosciences Inc. [APTO] reported its earnings at -$0.11 per share in the fiscal quarter closing of 9/29/2017. The Analysts for Wall Street were expecting to report its earnings at -$0.15/share signifying the difference of 0.04 and 26.70% surprise value. Comparing the previous quarter ending of 6/29/2017, the stated earnings were -$0.12 calling estimates for -$0.24/share with the difference of 0.12 depicting the surprise of 50.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Aptose Biosciences Inc. [NASDAQ:APTO] is 24.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 17.62. Now if looking for a valuation of this stock’s amount to book ratio is 4.59.

Insider Stories

The most recent insider trade was by Chow Gregory K., Executive VP & CFO, and it was the sale of 0.13 million shares on Jul 10. Rice William G., the Chair, President & CEO, completed a sale of 0.17 million shares on Jul 10. On Jul 10, Marango Jotin, Senior VP, Chief Bus. Officer, completed a sale of 62835.0 shares.